GLP-1 Insurance and Payment Hub (2026): Coverage Rules, Prior Authorization, Medicare and Medicaid, Savings Cards, HSA/FSA and Cash Options

Start with the plan, not the provider

The single most useful call is to your plan's member line: does it cover Zepbound and Wegovy for weight management, what are the prior-authorization criteria, and what is the copay at each tier? Write down who you spoke to. Providers can tell you what usually happens; only the plan can tell you what will happen to you.

Commercial insurance

Coverage for weight management is decided by the employer. Plans that cover it typically require prior authorization with a BMI of 30 or higher (27 with a comorbidity), documentation of a lifestyle program, sometimes step therapy, and sometimes continued weight loss to renew. Pharmacy benefit managers steer between brands: since July 2025 CVS Caremark has preferred Wegovy over Zepbound on its standard formulary. Where coverage exists, the manufacturers' savings cards bring commercially insured copays to as little as $25 a month. Where it does not, the cards offer little and the self-pay channels apply.

Medicare

Part D has covered Wegovy for cardiovascular risk reduction since 2024 and Zepbound for obstructive sleep apnea since 2025; weight management alone was historically excluded. The November 2025 manufacturer agreements announced a Medicare obesity pathway at $245 a month to the program and a $50 beneficiary copay, scheduled to begin during 2026, with criteria referencing BMI and comorbidities. Whether your plan has implemented it is a question for the plan. Medicare and Medicaid beneficiaries are excluded from manufacturer savings cards by law.

Medicaid

State by state. Roughly a dozen to sixteen states covered GLP-1s for obesity as of 2025 with varying prior-authorization rules; diabetes indications are covered nearly everywhere. The November 2025 agreements offered states the $245 price; uptake is a state decision.

Savings cards, HSA and FSA

Lilly's Zepbound card and Novo's Wegovy offer reduce copays for commercially insured patients with coverage and provide modest help without it; both exclude government-insured patients. HSA and FSA funds generally cover prescription medication, including compounded prescriptions dispensed by a pharmacy, and several providers (BMI MD, TrimRx, NexLife's plan pages mention it as well) advertise eligibility; confirm with the administrator and keep the prescription.

Telehealth programs that handle prior authorization

Ro (Body membership, $39 the first month then commitment-dependent), Calibrate (from about $199 a month, all 50 states), Form Health (physician-and-dietitian clinic billed through insurance where accepted), WeightWatchers Clinic and LifeMD build their programs around getting brand medication covered. They are the right choice for an insured patient and the wrong one for an uninsured patient, who would pay the program fee plus brand cash prices. The Zepbound and Wegovy pages list them with fees.

When coverage fails: the cash routes

Manufacturer direct: Zepbound vials $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) under Lilly's Self Pay Journey conditions; Wegovy pens $199 for qualifying initial fills then $349; oral Wegovy from $149 by dose. Compounded: verified flat-rate plans from $125 to $170 a month for tirzepatide and $88 to $139 for semaglutide. The cheapest-without-insurance page ranks them and the insurance article has the detail on the 2025 changes.

Payment plans and prepayment

Several providers discount 3-, 6- and 12-month prepayments by $20 to $100 a month. The saving is real; the risk is stopping early, which one in twenty trial participants did for side effects. Ask what is refunded, in writing, before prepaying, and consider a month-to-month plan for the first three months. The easiest-cancellation page records what each provider publishes.